Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)

perjantai 13. marraskuuta 2026 päivittänyt: Wayshine Biopharm, Inc.

An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.

This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

196

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kiina, 200123
        • Shanghai East Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Caicun Zhou, MD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 75 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Histologically or cytologically confirmed locally advanced or metastatic NSCLC
  2. Eligible for platinum-based doublet chemotherapy
  3. Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
  4. Tissue sample confirmed C797S positive by central lab using NGS
  5. At least one measurable target lesion per RECIST v1.1 criteria
  6. ECOG 0-1
  7. Adequate organ function and bone marrow function
  8. Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
  9. Male participants should agree to the use of contraceptive measures

Exclusion Criteria:

  1. Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
  2. Histological or phenotypic transformation
  3. Any severe or uncontrolled systemic disease
  4. ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
  5. Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
  6. A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
  7. Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
  8. Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
  9. Poorly controlled diabetes mellitus or hypertension
  10. History of other primary malignancies within two years
  11. Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
  12. Active infectious diseases (e.g., active HIV, HBV and HCV)
  13. Known alcohol or drug dependence
  14. Mental disorders or poor compliance
  15. The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: WSD0922-FU Tablet

Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

Muut nimet:
  • WSD0922
Active Comparator: Platinum-Based Doublet Chemotherapy

Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance):

Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle.

Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle.

Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

Muut nimet:
  • Sisplatiini
  • Karboplatiini
  • Pemetreksedi
  • Platinum-based doublet chemotherapy

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Progression Free Survival (PFS)
Aikaikkuna: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1

From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall Survival (OS)
Aikaikkuna: From the date of randomization to the date of death from any cause, assessed up to 36 months.

OS

From the date of randomization to the date of death from any cause, assessed up to 36 months.

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
PFS as assessed by investigator per RECIST 1.1
Aikaikkuna: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Objective Response Rate (ORR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

ORR as assessed by investigator and BICR per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Duration of Response (DOR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DoR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Disease Control Rate (DCR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DCR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Disease Progression (TTP)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTP by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Response (TTR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial ORR (icORR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icORR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial PFS (icPFS)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icPFS by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DOR (icDOR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDOR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DCR (icDCR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDCR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTP (icTTP)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTP by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTR (icTTR)
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
AE and SAE
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

AE and SAE per CTCAE 6.0

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
Aikaikkuna: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Päätutkija: Caicun Zhou, MD, Shanghai East Hospital

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Torstai 10. joulukuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. toukokuuta 2028

Opintojen valmistuminen (Arvioitu)

Keskiviikko 31. lokakuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Sunnuntai 8. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 19. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 19. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .